ECSP067096A - Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6 - Google Patents

Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6

Info

Publication number
ECSP067096A
ECSP067096A EC2006007096A ECSP067096A ECSP067096A EC SP067096 A ECSP067096 A EC SP067096A EC 2006007096 A EC2006007096 A EC 2006007096A EC SP067096 A ECSP067096 A EC SP067096A EC SP067096 A ECSP067096 A EC SP067096A
Authority
EC
Ecuador
Prior art keywords
indolilalkylamine
hydroxitriptamine
ligandos
metabolites
disorders
Prior art date
Application number
EC2006007096A
Other languages
English (en)
Inventor
Ronald Charles Bernotas
Chia-Cheng Shaw
Ping Cai
Youchu Wang
Chung-Chiee Paul Wang
Zhi Wang
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35033547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP067096(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP067096A publication Critical patent/ECSP067096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/033—Uronic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención suministra un compuesto de fórmula I y el uso de estos para tratamiento terapéutico de trastornos que se relacionan con o se afectan por el receptor 5-HT6.
EC2006007096A 2004-06-23 2006-12-19 Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6 ECSP067096A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58229004P 2004-06-23 2004-06-23

Publications (1)

Publication Number Publication Date
ECSP067096A true ECSP067096A (es) 2007-02-28

Family

ID=35033547

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006007096A ECSP067096A (es) 2004-06-23 2006-12-19 Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6

Country Status (19)

Country Link
US (1) US7498327B2 (es)
EP (1) EP1758898A1 (es)
JP (1) JP2008504267A (es)
KR (1) KR20070041514A (es)
CN (1) CN1976928A (es)
AR (1) AR049449A1 (es)
AU (1) AU2005258025A1 (es)
BR (1) BRPI0512540A (es)
CA (1) CA2570818A1 (es)
CR (1) CR8825A (es)
EC (1) ECSP067096A (es)
IL (1) IL180198A0 (es)
MX (1) MX2007000182A (es)
NO (1) NO20070065L (es)
PA (1) PA8637801A1 (es)
PE (1) PE20060303A1 (es)
RU (1) RU2006146923A (es)
TW (1) TW200606148A (es)
WO (1) WO2006002125A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101613B2 (en) 2006-02-15 2015-08-11 Neurim Pharmaceuticals (1991) Ltd. Methods for treating neurological disease
US7635710B2 (en) 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
EP1953153A1 (en) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
EP2053052A1 (en) 2007-10-23 2009-04-29 Laboratorios del Dr. Esteve S.A. Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide
CN104725295B (zh) 2013-12-20 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489767A (en) * 1966-01-12 1970-01-13 Sumitomo Chemical Co 1-(phenylsulfonyl)-3-indolyl aliphatic acid derivatives
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US6380166B1 (en) 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
AU2002357270B2 (en) * 2001-12-20 2007-06-14 Wyeth Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
US20060089353A1 (en) * 2003-03-06 2006-04-27 Maki Iwahashi Indole derivative compounds and drugs containing the compounds as the active ingredient
JP4845730B2 (ja) * 2003-07-17 2011-12-28 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity

Also Published As

Publication number Publication date
WO2006002125A1 (en) 2006-01-05
BRPI0512540A (pt) 2008-03-25
CR8825A (es) 2007-08-28
CA2570818A1 (en) 2006-01-05
PA8637801A1 (es) 2006-06-02
PE20060303A1 (es) 2006-05-19
AR049449A1 (es) 2006-08-02
MX2007000182A (es) 2007-03-23
AU2005258025A1 (en) 2006-01-05
NO20070065L (no) 2007-01-04
CN1976928A (zh) 2007-06-06
JP2008504267A (ja) 2008-02-14
IL180198A0 (en) 2007-06-03
US20060003945A1 (en) 2006-01-05
TW200606148A (en) 2006-02-16
EP1758898A1 (en) 2007-03-07
US7498327B2 (en) 2009-03-03
KR20070041514A (ko) 2007-04-18
RU2006146923A (ru) 2008-07-27

Similar Documents

Publication Publication Date Title
CR7643A (es) Derivados de 1-heterociclialquil -3-sulfonilazaindol o azaindazol como ligandos de 5-hidroxitriptamina-6
ECSP034810A (es) Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
CR8644A (es) Compuestos de imidazol para el tratamiento de transtornos neurodegenerativos
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
UY31065A1 (es) Heterociclos ciclicos
UY28708A1 (es) Heterociclos sustituídos y usos de los mismos
ECSP088620A (es) 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
CR11303A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
GT200800214A (es) Antagonistas de los piridil amida de los canales de calcios de tipo t
UY28752A1 (es) Agentes terapeuticos
NI201000090A (es) Agonistas novedosos de los receptores de glucocorticoides.
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
UY28144A1 (es) Agentes terapéuticos
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
CR11309A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonista de la histamnia-3
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
ECSP088176A (es) Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6